R&D FACILITIES

With our strong R&D focus, competency to generate intellectual property and extensive experience in development and manufacturing of modified release formulations, we enjoy the trust of customers in more than ten countries in the Middle-East, CIS, Latin America, Africa and South-East Asia.

Newly Developed Products
- Dimethyl Fumarate Pellets 30% & 55%- To Treat Multiple Sclerosis
- Aprepitant Pellets 40% – Potent Anti-Emetic
- Dabigatran Etexilate Pellets 43% – Potent Anti-Coagulant
- Metoprolol Succinate Extended Release Micro (# 28 – 40) Pellets 60% – Antihypertensive
- Ready to Compress Granules of Orlistat 6% for Chewable Tablets 27 mg – Obesity Management
- Choline Fenofibrate Delayed Release Pellets 60% – Lipid Lowering Agent
- Blended Pellets Of TamsulosinHCl&Dutasteride Pellets – To Treat BPH
Services Offered
- Extensive Formulation development assistance including
  - API Characterization
  - Pre-formulation & Formulation
  - Prototype construction
  - Analytical Method Development and Validation
  - Process Optimization
  - Stability Studies and Bioequivalence Studies
- Customize drug-release profiles/non infringing compositions and processes.
- Regulatory and Documentation support.

R&D FACILITIES

Newly Developed Products

Services Offered